Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TVB-2640 in advanced solid tumors
NCT02223247Phase 1Completed
- Sponsor
- Sagimet Biosciences
- Start
- Nov 2013
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of denifanstat in solid tumor (2 arms), sponsored by Sagimet Biosciences. Primary endpoints: Maximum Tolerated Dose at 1.5 years and Dose-Limiting Toxicities. Started Nov 2013; status: completed.
02
Drugs
denifanstat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02223247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223247.